玻璃体内注射贝伐单抗治疗伴有脂质沉积的角膜新生血管。

Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition.

机构信息

Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.

出版信息

Cornea. 2011 Jan;30(1):60-6. doi: 10.1097/ICO.0b013e3181e458c5.

DOI:10.1097/ICO.0b013e3181e458c5

PMID:20847676

Abstract

PURPOSE

To determine the effects on corneal neovascularization (NV) and lipid deposition after subconjunctival injection of bevacizumab in patients who had NV associated with lipid keratopathy.

METHODS

A case interventional study enrolled 18 patients (18 eyes) with lipid keratopathy. We gave monthly subconjunctival injections of bevacizumab from 3 to 10 times during the follow-up period according to the clinical response. We evaluated the centricity, extent, and percentage of involved corneal surface (PICS) of the corneal NV; the density and PICS of the corneal lipid deposition; and best-corrected visual acuity before and after treatment. We analyzed the treatment effects using Wilcoxon and Student t tests.

RESULTS

After the treatment, the change in best-corrected visual acuity was less than 2 lines. The extent, centricity, and PICS of the corneal NV and the density and PICS of the corneal lipid deposition decreased significantly after treatment (P = 0.014/0.002/0.001 and 0.001/<0.001, respectively). No eyes had side effects.

CONCLUSIONS

The effects of subconjunctival injection of bevacizumab in treating corneal NV associated with lipid deposition were significant in some patients.

摘要

目的

观察玻璃体内注射贝伐单抗治疗伴有脂质沉积的角膜新生血管（NV）的效果。

方法

本病例干预研究纳入了 18 例（18 只眼）伴有脂质沉积的角膜新生血管患者。根据临床反应，在随访期间每月进行 3 至 10 次玻璃体内注射贝伐单抗。评估角膜 NV 的中心性、范围和受累角膜表面百分比（PICS）；角膜脂质沉积的密度和 PICS；以及治疗前后的最佳矫正视力。采用 Wilcoxon 和学生 t 检验分析治疗效果。